Johnson & Johnson's Decision to Sell Its Orthopedic Business: A Layman's Explanation of the Business Logic Behind the Giant's Downsizing
Hello everyone, I'm your financial journalist. Today, we're talking about a big news story that's made a splash in the medical community: Johnson & Johnson (J&J) might be selling one of its most prestigious orthopedic businesses.
This isn't a small deal; it's a super-large transaction worth nearly $20 billion (about 140 billion yuan). If the deal goes through, it will be one of the largest mergers and acquisitions in the global medical device industry in 2026.
Many people might wonder, isn't J&J one of the world's leading pharmaceutical companies? Why would they sell their most valuable business? What's really going on behind the scenes? Today, we'll break down this news into five key points in plain language so you can understand it easily.
---
1. Why Sell?
The reason J&J wants to sell this business is that it's not growing as it used to and it's also involved in legal disputes.
First, let's understand why J&J wants to part with this business. Some might think that selling an important part of the company would result in losses, but the opposite is true. Keeping it is actually causing problems for J&J.
Firstly, the growth is too slow and is dragging down overall performance. Think of J&J as a large family with several business units. Some of these units (like its cardiovascular business) are doing very well, with significant progress, while others (like orthopedics) are not. For example, the orthopedic business only grew by 1.1% in 2025, compared to a 16.8% increase in the cardiovascular business. In the capital market, slow growth is considered negative. Investors prefer companies with high growth rates, and the orthopedic business has become a weak link in J&J's financial reports.
Secondly, the business is embroiled in legal issues. J&J's orthopedic subsidiary, DePuy Synthes, is facing lawsuits from over 10,000 people in the United States due to design flaws in its ASR hip replacement system. Although most of these lawsuits have been resolved, 128 cases remain unresolved. For a company like J&J, which values a perfect reputation, these potential compensation and reputational risks are a major burden. Selling this business allows them to get rid of these issues.
In short: The orthopedic business is no longer profitable for J&J, but it's too valuable to abandon. To protect the overall stock price and profit margins, selling it is the more rational choice.
---
2. The “Butterfly Effect” of China’s Price Negotiations: Price Wars Spread Globally
You might wonder how a global giant like J&J could be affected by price negotiations in the Chinese market.
The answer is that the impact is significant, and the Chinese market has set an example for the entire orthopedic industry. In the past, orthopedic supplies (such as artificial joints and spinal fusion devices) were highly profitable. However, through China’s “national procurement” (government-led bidding), the prices of these products have been significantly reduced. For example, what used to cost thousands of dollars might now cost just a few hundred dollars. This has shown the world that orthopedic supplies are not as mysterious as they once were, and their technical barriers are not as high, meaning prices can be lowered.
What does this mean for J&J?
1. Profit margins are being squeezed: In the huge Chinese market, J&J has to accept lower prices, which reduces its overall profit margins.
2. Global pricing benchmarks are changing: As prices in China decrease, hospitals and patients in other countries will use these as a reference, forcing J&J to adjust its pricing strategies globally, further squeezing its profits.
Therefore, J&J's decision to sell its orthopedic business is also a way to escape a “low-profit, high-competition” market environment.
---
3. J&J’s Long-Term Strategy: Selling Old Business to Invest in New, Higher-Margin Areas
This isn't the first time J&J has used this strategy. If you know J&J's history, you'll see that it has a clear approach of “cutting losses and making precise acquisitions.”
For example:
- 2015: J&J sold its highly competitive and low-profit cardiovascular stent business (Cordis).
- After 2022: J&J spent nearly $40 billion acquiring two companies specializing in cardiac assist devices and endovascular shock waves.
- Result: These new acquisitions led to double-digit growth and high profits for J&J in 2025.
J&J’s logic is simple: it sells businesses that are mature, highly competitive, low-profit, and growing slowly, and buys businesses that are technologically advanced, less competitive, and more profitable. This time, the same logic applies to the orthopedic business. J&J’s CEO and CFO have stated that the innovation potential in orthopedics no longer aligns with the company’s current focus. In other words, J&J doesn’t want to continue competing in the orthopedic market; instead, it wants to invest in more profitable and future-oriented areas.
---
4. A Global Trend: Global Giants are Downsizing to Improve Efficiency
J&J is not alone in this trend. The entire global medical device industry is undergoing a major reshuffle:
- Zimmer Biomet: Sold its spinal and dental businesses.
- Philips: Sold its emergency care business.
- Baxter: Sold its kidney business.
- Medtronic: Sold its diabetes business and has been aggressively acquiring companies in the cardiovascular and neurointerventional fields.
Why are they doing this?
The market has changed:
1. Limited resources: Companies have limited funds and energy to spread across all areas.
2. Intense competition: Traditional businesses are highly competitive, resulting in thin profit margins.
3. Investors prefer high profits and fast growth.
J&J’s decision to sell its orthopedic business is in line with this trend. Companies are focusing on cutting unprofitable and non-strategic businesses to concentrate resources on their most core and competitive areas.
---
5. Future Prospects: J&J Becoming a “High-Tech Company,” and the New Owner of the Orthopedic Business May Do Better
Let’s look at the implications of this transaction for the future:
For J&J: By selling its orthopedic business, J&J will become more focused on high-growth, high-profit areas like cardiovascular and neurointerventional technologies. J&J’s CFO, Joe Walker, said plainly, “The orthopedic business might perform better under new ownership.” This means J&J expects the new owner to be more flexible in responding to market changes, such as investing more in surgical robots (like competing with Stryker’s Mako) or adjusting pricing strategies independently.
For the orthopedic industry: The acquisition by a private equity giant like Apollo means DePuy Synthes will enter a new phase driven by capital. Apollo may help optimize costs and improve efficiency, and the company might even go public independently. The competitive landscape could change, with Stryker, already a leader in surgical robots, possibly gaining an even greater advantage. J&J’s orthopedic business might become more innovative and try to regain its position.
For consumers: In the short term, there won’t be much change in product supply and services. In the long term, the industry might see faster innovation (such as robotic surgeries and 3D-printed joints) due to increased capital investment, but prices may fluctuate as companies strive for higher profits. However, given the trend of price reductions in China, overall prices are likely to remain lower.
---
Conclusion
J&J’s decision to sell its orthopedic business is not a simple decision but a strategic move to improve efficiency and focus on more profitable areas. It reflects a broader trend where global giants are downsizing to become more efficient and focused. This is not just about J&J; the entire medical device industry is reorganizing to be more profitable and competitive.
For investors, this signals that future pharmaceutical giants will not be large and comprehensive companies but will be specialized and efficient. Those that can concentrate their resources on the most valuable areas will be the ones to succeed in the next decade.